Add to ORKGMultiple-drug chemotherapy has markedly improved the survival of patients with non oat-cell bronchial carcinoma who respond to it. Further progress can be expected from the use of new cytostatic drugs which may increase the rate and the duration of the responses.SCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe
International audienceLung cancer is the leading cause of cancer-related mortality and more than hal...
219 cases of small cell carcinoma of the lung are reviewed. The 5-year survival rate is less than 5%...
Dans les pays occidentaux, le cancer bronchique (CB) est la cause la plus fréquente dedécès par canc...
MODEST RESULTS TILL NOW: Despite progress in the treatment of bronchial cancer (BC) over the last 20...
In approximately 80% of the patients with limited disease, the administration of treatment, either c...
Single agent chemotherapy of advanced lung cancer is still unsatisfactory. The most encouraging resu...
A survey is presented of the current chemotherapy of bronchial carcinoma, excluding small cell carci...
Chemotherapy in non-small cell bronchial carcinoma Each year about 40 000 people in the United King-...
Le cancer du poumon représente la première cause de mortalité par cancer en France ainsi qu'au nivea...
POITIERS-BU Médecine pharmacie (861942103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
The precocity of the diagnosis of non small lung cancers (NSCLC) is crucial. Only 30% of these tumou...
The administration of multiple cytostatic drugs on a weekly basis has been proposed as a new intensi...
Les cancers broncho-pulmonaires sont, toujours en 2010, la principale cause de décès par cancer dans...
The EORTC Lung Working Party is a regional cooperative group that has investigated various chemother...
During the last decade, molecular biology has considerably progressed allowing a better knowledge of...
International audienceLung cancer is the leading cause of cancer-related mortality and more than hal...
219 cases of small cell carcinoma of the lung are reviewed. The 5-year survival rate is less than 5%...
Dans les pays occidentaux, le cancer bronchique (CB) est la cause la plus fréquente dedécès par canc...
MODEST RESULTS TILL NOW: Despite progress in the treatment of bronchial cancer (BC) over the last 20...
In approximately 80% of the patients with limited disease, the administration of treatment, either c...
Single agent chemotherapy of advanced lung cancer is still unsatisfactory. The most encouraging resu...
A survey is presented of the current chemotherapy of bronchial carcinoma, excluding small cell carci...
Chemotherapy in non-small cell bronchial carcinoma Each year about 40 000 people in the United King-...
Le cancer du poumon représente la première cause de mortalité par cancer en France ainsi qu'au nivea...
POITIERS-BU Médecine pharmacie (861942103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
The precocity of the diagnosis of non small lung cancers (NSCLC) is crucial. Only 30% of these tumou...
The administration of multiple cytostatic drugs on a weekly basis has been proposed as a new intensi...
Les cancers broncho-pulmonaires sont, toujours en 2010, la principale cause de décès par cancer dans...
The EORTC Lung Working Party is a regional cooperative group that has investigated various chemother...
During the last decade, molecular biology has considerably progressed allowing a better knowledge of...
International audienceLung cancer is the leading cause of cancer-related mortality and more than hal...
219 cases of small cell carcinoma of the lung are reviewed. The 5-year survival rate is less than 5%...
Dans les pays occidentaux, le cancer bronchique (CB) est la cause la plus fréquente dedécès par canc...